Ontology highlight
ABSTRACT: Background
Clinical applicability of the Academic Research Consortium High Bleeding Risk (ARC-HBR) criteria in East-Asian patients receiving potent antiplatelet therapy for acute coronary syndromes (ACS) is still undetermined.Objectives
The purpose of this study was to validate the ARC definition for HBR in East-Asian patients with ACS for invasive management.Methods
We analyzed data from the TICAKOREA (Ticagrelor Versus Clopidogrel in Asian/Korean Patients With ACS Intended for Invasive Management) trial and randomly assigned 800 Korean ACS subjects to receive, in a 1:1 ratio, ticagrelor or clopidogrel. Patients were considered HBR if they met at least 1 major or 2 minor ARC-HBR criteria. The primary bleeding endpoint was Bleeding Academic Research Consortium 3 or 5 bleeding and the primary ischemic endpoint was a major adverse cardiovascular event (MACE) (a composite of cardiovascular death, myocardial infarction, or stroke) at 12 months.Results
Among 800 randomized patients, 129 (16.3%) were categorized HBR patients. HBR patients, compared with non-HBR patients, had a higher incidence of Bleeding Academic Research Consortium 3 or 5 bleeding (10.0% vs 3.7%; HR: 2.98; 95% CI: 1.52-5.86; P < 0.001) and MACE (14.3% vs 6.1%; HR: 2.35; 95% CI: 1.35-4.10; P = 0.002). The relative treatment effect of ticagrelor or clopidogrel on primary bleeding and ischemic outcomes were different between each group.Conclusions
This study validates the ARC-HBR definition in Korean ACS patients. Approximately 15% of patients qualified as HBR patients who were at increased risk not only for bleeding but also for thrombotic events. The clinical application of ARC-HBR to determine the relative effect of different antiplatelet regiments should be further investigated. (Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients with Acute Coronary Syndromes Intended for Invasive Management [TICA KOREA]; NCT02094963).
SUBMITTER: Lee J
PROVIDER: S-EPMC10261889 | biostudies-literature | 2023 Jun
REPOSITORIES: biostudies-literature
Lee Jinho J Kim Min-Ju MJ Kim Mijin M Park Jinsun J Kim Hoyun H Cho Suji S Choi Yeonwoo Y Lee Junghoon J Kim Ju Hyeon JH Cha Sung Joo SJ Kim Tae Oh TO Kang Do-Yoon DY Lee Pil Hyung PH Ahn Jung-Min JM Park Seung-Jung SJ Park Duk-Woo DW
JACC. Asia 20230207 3
<h4>Background</h4>Clinical applicability of the Academic Research Consortium High Bleeding Risk (ARC-HBR) criteria in East-Asian patients receiving potent antiplatelet therapy for acute coronary syndromes (ACS) is still undetermined.<h4>Objectives</h4>The purpose of this study was to validate the ARC definition for HBR in East-Asian patients with ACS for invasive management.<h4>Methods</h4>We analyzed data from the TICAKOREA (Ticagrelor Versus Clopidogrel in Asian/Korean Patients With ACS Inten ...[more]